Shares of Sudeep Pharma made a strong market debut on Friday, November 28, listing at a 23% premium over.
The issue price of ₹593. The stock opened at ₹730 on the NSE and ₹733.95 on the BSE, before edging higher to an intraday level of ₹738 per share.
The upbeat listing follows an exceptional market response to the IPO, which saw an overall subscription of 93.71 times. The QIB portion was subscribed 213.08x, the NII category 116.72x, and the retail segment 15.65x, underscoring strong interest across investor classes.
Should You Buy, Hold or Sell Sudeep Pharma?
According to Shivani Nyati, Head of Wealth at Swastika Investmart, the company’s steady business profile supported the robust listing. Sudeep Pharma’s diversified presence across pharma excipients, nutraceutical ingredients, and specialty inputs, along with strong export potential and longstanding ties with global pharma giants, contributed to the strong debut.
However, Nyati cautioned that investors should keep an eye on factors such as margin stability, volatility in raw material prices, and rising competition in the specialty ingredients space.
Strategy Call:
Allottees may consider booking partial profits after the listing pop.
Long-term investors bullish on pharma ingredients may choose to hold, with a suggested stop-loss at ₹690.
IPO Snapshot
The three-day IPO concluded on November 25 and consisted of a ₹95 crore fresh issue and an ₹800 crore offer for sale by promoter entities. The company also raised ₹268.5 crore from anchor investors prior to the issue.
Fresh issue proceeds of approximately ₹75.81 crore will fund capital expenditure, including machinery procurement for the company’s Nandesari Facility 1 in Gujarat, along with general corporate purposes.
About Sudeep Pharma
Sudeep Pharma is a technology-driven manufacturer of excipients and specialty ingredients catering to the pharmaceutical, food, and nutrition industries. The company is among the largest producers of food-grade iron phosphate, with a combined annual capacity of 72,246 metric tons (as of June 30, 2025).
It services 1,100+ customers, including marquee global names such as Pfizer, Merck Group, Danone SA, Aurobindo Pharma, Mankind Pharma, and Cadila Pharmaceuticals.
The IPO was managed by ICICI Securities and IIFL Capital Services, with MUFG Intime India Pvt Ltd as registrar.
Comments are closed.